Adlai Nortye, a Chinese clinical-stage biopharmaceutical company focusing on developing immuno-oncology medicines., has raised nearly US$100 million in a series C round financing, led by Tigermed and Yingke PE. ATCG Holdings, Shengxin Venture Capital, Puxin Ruiyuan, Hongtu No. 5 and a fund under ICBC Asset Management (Global) also participated in the round. Adlai Nortye was […]

Chinese Biopharma Firm Adlai Nortye Raises $100M In Series C Round comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.